InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by MITCHELL DEAN J, Director. Officer active across 4 companies, notably ImmunoGen, Inc.. In total, 6 disclosures have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €42k. History available since 3 September 2021. The latest transaction was disclosed on 8 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations6 total
25,000 shares@ US$1.80750.0006% mcap100.0% of flowCommon StockSEC:0001689548-22-000075:0
Ideal exit: 5 Mar 2023 (T+270)
9,852 shares0Ordinary SharesSEC:0001415889-22-004332:0
16,212 sharesCommon StockSEC:0000950103-22-005401:0
27,832 shares@ US$2.030.0032% mcap100.0% of flowCommon StockSEC:0000950103-22-003222:0
5,000 shares@ US$1.84100.0% of flowCommon StockSEC:0001179110-21-008587
5,000 shares@ US$1.8450.0% of flowCommon StockSEC:0001179110-21-008587:0
6 of 6 declarations
About MITCHELL DEAN J
Dean J. Mitchell is a Board Member at ImmunoGen, Inc., PRECIGEN, INC., and Theravance Biopharma, Inc. He plays a vital role in the governance of these companies, bringing his expertise in biopharmaceuticals and innovation. Mitchell contributes to formulating strategies that promote growth and sustainable development.
